Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAKK 01/18: Reduced intensity radio-chemotherapy for Stage IIA/B seminoma
2023-509663-24-00Phase 2Authorised
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Aug 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of carboplatin, etoposide and cisplatin in Pure seminoma (2 cohorts), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Progression free survival at 3 years. Planned start Aug 2024; status: authorised.
02
Drugs
carboplatinetoposidecisplatin
03
Conditions
Pure seminoma
Beyond the preview
Go deeper on 2023-509663-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509663-24-00.